Date	Period	Revenue/Estimate	Earnings Call
--	2025/Q4	-- / 86.481B	--
Feb 12, 2025	2025/Q3	-- / 89.537B	--
Nov 13, 2024	2025/Q2	70.726B / 71.022B	--
Aug 7, 2024	2025/Q1	68.356B / 67.660B	--
May 13, 2024	2024/Q4	69.677B / 71.304B	--

DatePeriodRevenue/EstimateEarnings Call

--2025/Q4-- / 86.481B--

Feb 12, 20252025/Q3-- / 89.537B--

Nov 13, 20242025/Q270.726B / 71.022B--

Aug 7, 20242025/Q168.356B / 67.660B--

May 13, 20242024/Q469.677B / 71.304B--

Unlock Free Earnings Estimates

Open Account

Rohto Pharmaceutical: Confirmation letter

Nov 13 20:17 ET

Rohto Pharmaceutical: Half Year Report - Term 89 (2024/04/01 - 2025/03/31)

Nov 13 20:16 ET

Rohto Pharmaceutical: Overview of consolidated financial results for the fiscal year ending March 31, 2025 (4/1 to 9/30)

Nov 13 01:30 ET

Rohto Pharmaceutical: Rohto Pharmaceutical Co., Ltd. 89th Interim Term (4/1 to 9/30) reference materials

Nov 13 01:30 ET

Symbol Price % Chg

See the daily top gainer.

Analysis

Updated: Dec 18, 2024

Buy

No Data